Sunshine Biopharma, Inc.'s Adva-27a Found to be Effective at Killing Multidrug Resistant Lung Cancer Cells
6/26/2012 11:05:22 AM
MONTREAL, Quebec--(BUSINESS WIRE)--Sunshine Biopharma Inc. (OTCBB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it has completed a cytotoxicity study of its lead compound, Adva-27a, in H69AR, a Multidrug Resistant Small Cell Lung Cancer cell line. Cytotoxicity studies measure the ability of a drug to destroy cancer cells in vitro. The results of the study showed that Adva-27a is significantly more effective at killing Multidrug Resistant Small Cell Lung Cancer cells than Etoposide, the current commonly used drug for this type of cancer. This is the second form of Multidrug Resistant Cancer that Adva-27a has shown effectiveness against. The first, which we had announced on July 11, 2011, was MCF-7/MDR Multidrug Resistant Breast Cancer.
comments powered by